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Hyperpolarization-activated cyclic nucleotide-gated (HCN) channels are expressed as
four different isoforms (HCN1-4) in the heart and in the central and peripheral nervous
systems. HCN channels are activated by membrane hyperpolarization at voltages
close to resting membrane potentials and carry the hyperpolarization-activated current,
dubbed If (funny current) in heart and Ih in neurons. HCN channels contribute in several
ways to neuronal activity and are responsible for many important cellular functions,
including cellular excitability, generation, and modulation of rhythmic activity, dendritic
integration, transmission of synaptic potentials, and plasticity phenomena. Because of
their role, defective HCN channels are natural candidates in the search for potential
causes of neurological disorders in humans. Several data, including growing evidence
that some forms of epilepsy are associated with HCN mutations, support the notion
of an involvement of dysfunctional HCN channels in different experimental models of
the disease. Additionally, some anti-epileptic drugs are known to modify the activity of
the Ih current. HCN channels are widely expressed in the peripheral nervous system and
recent evidence has highlighted the importance of the HCN2 isoform in the transmission
of pain. HCN channels are also present in the midbrain system, where they finely
regulate the activity of dopaminergic neurons, and a potential role of these channels
in the pathogenesis of Parkinson’s disease has recently emerged. The function of
HCN channels is regulated by specific accessory proteins, which control the correct
expression and modulation of the neuronal Ih current. Alteration of these proteins
can severely interfere with the physiological channel function, potentially predisposing
to pathological conditions. In this review we address the present knowledge of the
association between HCN dysfunctions and neurological diseases, including clinical,
genetic, and physiopathological aspects.
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Introduction
The class of hyperpolarization-activated cyclic nucleotide-gated (HCN) channels comprises four
human isoforms (HCN1-4) and belongs to the superfamily of voltage-dependent potassium (Kv)
and cyclic nucleotide-gated (CNG) channels. HCN channels are unique in that they are dually acti-
vated by voltage hyperpolarization and intracellular cAMP (DiFrancesco, 1999, 2006; Barbuti et al.,
2007a; Baruscotti et al., 2010).
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Since they are constitutively open at voltages near to the
resting membrane potential and, being permeable to both
Na+ and K+ ions, carry at these voltages an inward cur-
rent, HCN channels are well equipped to control voltage-
dependent mechanisms, such as neuronal excitability, and related
functions.
In neurons, HCN channels carry the hyperpolarization -
activated (Ih) current. The four isoforms are diﬀerently dis-
tributed: HCN1, 2 and 4 are widely expressed and contribute to
the generation of neuronal activity, while the role of HCN3 is less
clear. In neurons, HCN are responsible for several important cel-
lular functions, including the contribution to cellular excitability,
and plasticity phenomena in the brain. One of the most speciﬁc
functions of HCN channels is their involvement in the genera-
tion and modulation of rhythmic activity, which is typiﬁed by the
role they play in the spontaneous activity and frequency control
of pacemaker cells of the heart (DiFrancesco, 1993; Pape, 1996;
Robinson and Siegelbaum, 2003; Barbuti et al., 2007a).
As expected from the established role of HCN channels in
neurons, in the last few years new evidence has emerged linking
HCN channels’ dysfunctions to diﬀerent neurological disorders,
in accordance with the view that altered pacemaker activity can
act as a strong pathogenic mechanism.
The vast majority of such data have been obtained in the
ﬁeld of epilepsy (Dyhrfjeld-Johnsen et al., 2009; Baruscotti et al.,
2010; DiFrancesco et al., 2011; Reid et al., 2012; Shah et al., 2013).
Together with data from animal models showing that HCN
dysfunction can lead to epileptogenesis, evidence is accumu-
lating to indicate that some inheritable forms of epilepsy can
be associated in human patients with HCN genetic muta-
tions leading to altered Ih current function and increased neu-
ronal excitability. Although a comprehensive picture of the
genetic basis of epilepsy is far from complete, these new
data contribute importantly to a deeper understanding of
the processes responsible for causative changes in neuronal
excitability.
As well as in the central nervous system (CNS), HCN channels
are also widely expressed in the peripheral nervous system (PNS),
where their function is important in the perception, modulation,
and transmission of sensory signals, including pain. Recent data
demonstrate a central role of the HCN2 isoform in the trans-
mission of neuropathic and inﬂammatory pain (Emery et al.,
2011).
Moreover, HCN channels are expressed in the midbrain sys-
tem, where they control the oscillatory activity of dopaminergic
neurons. In line with this evidence, a new potential role of HCN
channels dysfunction is also emerging in the pathogenesis of
Parkinson’s disease (PD).
Full knowledge of the pathogenic mechanisms under-
lying these debilitating neurological diseases and the
role played by aberrant HCN channel function is not at
hand. However, a more comprehensive understanding is
desirable in many respects, particularly in view of the
possibility to identify new potential therapeutic strate-
gies (DiFrancesco and Borer, 2007; Dunlop et al., 2009;
Wickenden et al., 2009; Postea and Biel, 2011; Reid et al.,
2012; Shah et al., 2013).
In this review we address the current knowledge of HCN
channels properties and their role of dysfunctional behavior in
human neurological diseases.
Epilepsy
Epilepsy is a neurological disorder characterized by recurrent
paroxysmal episodes of brain electrical dysfunction. Seizures are
caused by an excessive and sudden electrical discharge of neu-
rons of the CNS. Epilepsy is a common disorder, aﬀecting about
4% of the general population, often involving children, and young
adults, with a very high cost to society in terms of direct expenses
for the public health service and disabilities. Epilepsy aﬀects at
least 50 million people worldwide, with a global mortality rate
higher than cancer.
The cause of the disease remains unknown in about 60% of
cases, which are referred to as “idiopathic.” About 30% of idio-
pathic epilepsies are inheritable and aﬀect several members of
the family. Current research reveals that several types of epilepsy,
both familiar, and sporadic, have a genetic component mainly
linked to mutations in genes encoding either voltage-gated (Na+,
Ca2+, and K+) or ligand-gated (GABAA and cholinergic nico-
tinic receptor) channels (Avanzini et al., 2007; Mantegazza et al.,
2010; Thomas and Berkovic, 2014).
The recognition that certain epileptic syndromes are chan-
nelopathies has opened new perspectives in the understanding
of the molecular pathophysiology of seizure disorders. Following
ﬁndings of causative links between epileptic syndromes and
mutations in voltage-gated or ligand-gated channels, the fam-
ily of ion channels involved in epileptogenic channelopathies
has grown rapidly. Together with the ion channel types whose
involvement has been established early, another family that
according to more recent data play a role in the pathogenesis of
inheritable epilepsy is the family of HCN channels. Because of
their established role inmodulating neuronal excitability, a modi-
ﬁcation of the function of HCN channels is clearly potentially able
to cause uncontrolled action potential ﬁring and provide a back-
ground setting for the development of epilepsy (Baruscotti et al.,
2010).
In the last few years, evidence for a potential relevant role
of HCN channels in the pathogenesis of epilepsy has grown
considerably. Many results derive from animal models, but a sub-
stantial bulk of recent data shows thatHCN dysfunctional genetic
mutations associated with epilepsy are also expressed in human
patients.
Animal Models
Several data supporting a link between functional alteration of
HCN channels and epileptogenesis have been obtained by studies
of HCN1 and HCN2 knock-out mouse models.
For example, cortical excitability and epileptogenesis are
enhanced by loss of HCN1 expression and abolishment of Ih in
HCN1-null mice, since lack of this channel increases the dendritic
input resistance in cortical neurons, leading to greater synaptic
integration, and ﬁring (Huang et al., 2009). In the same HCN1-
null mouse model, greater dendritic excitability, and temporal
Frontiers in Cellular Neuroscience | www.frontiersin.org 2 March 2015 | Volume 9 | Article 71
DiFrancesco and DiFrancesco Dysfunctional HCN in neurological diseases
summation were also observed in hippocampal CA1 pyrami-
dal neurons (Nolan et al., 2004; Tsay et al., 2007). In another
study, in agreement with a role for Ih downregulation in epilep-
togenesis, HCN2-deﬁcient mice generated by a global knock-
out model were shown to exhibit spontaneous absence seizures
(Ludwig et al., 2003). Generalized spike–wave absence seizures
were also observed in spontaneous HCN2 mutant (apathetic)
mice, where channel proteins are truncated at the C termi-
nus and poorly expressed (Chung et al., 2009). Moreover, dif-
ferent genetic models of absence epilepsy such as WAG/Rij
and GABAAγ2(R43Q) revealed an altered expression of HCN1
associated with the occurrence of seizures (Kole et al., 2007;
Phillips et al., 2014).
The remodeling of HCN channels expression also provides
an important contribution to the epileptogenic network and
seizure production. In the immature animal brain, sustained
febrile seizures (FS) increase neuronal excitability and the pre-
disposition to develop epilepsy in adults, by modifying the mem-
brane expression of HCN isoforms 1 and 2 (Dube et al., 2000;
Brewster et al., 2002). Seizures provoke a prolonged remodeling
of HCN1 and HCN2 expression, supporting the presence of a
transcriptional channelopathy involving HCN channels which
contributes to the development of epilepsy (Richichi et al., 2008).
Similar observations can be made in the epileptic human brain
tissue, where the expression of HCN channels is altered, indicat-
ing that the HCN isoforms are dynamically regulated in humans
in vivo, as well as in the experimental hippocampal epilepsy
(Bender et al., 2003).
In accordance with the observations above, diﬀerent models
of temporal lobe epilepsy (TLE), the most frequent form of par-
tial epilepsy in humans, revealed a signiﬁcant downregulation
of HCN channels expression following pharmacological status
epilepticus (SE), with increased neuronal excitability. This could
have important implications for both the process of epileptogene-
sis and maintenance of the epileptic state (Jung et al., 2007, 2011;
Powell et al., 2008).
Human Patients
Despite the availability of a substantial amount of experimen-
tal data on animal models supporting the role played by HCN
channels in the pathogenesis of epilepsy, evidence from human
patients is still limited.
Tang et al. (2008), published a pilot study of 84 patients with
a non-inheritable form of idiopathic generalized epilepsy (IGE)
and searched for mutations in HCN1 and HCN2 in this cohort.
They identiﬁed, among others, a single point mutation in the
C-linker region of HCN2, aﬀecting a highly conserved and func-
tionally relevant residue (R527Q). However, a conclusive proof
that this mutation is causative was lacking, since functional stud-
ies did not show statistically signiﬁcant diﬀerences between the
properties of mutant and wild-type channels. Dibbens and col-
leagues later reported that in a population of children with FS
and genetic epilepsy with FS plus (GEFS+), the rate of appear-
ance of anHCN2 variant characterized by a triple proline deletion
(delPPP, p.719–721) was signiﬁcantly higher than in the gen-
eral population. Heterologous expression studies indicated that
delPPP channels carry a 35% larger Ih current than wild-type
channels, suggesting that delPPP behaves as a gain-of-function
mutation (Dibbens et al., 2010). However, while statistical signif-
icance is a necessary condition to demonstrate a link between
mutation and diseased phenotype, the study did not address how
the mutation alters the functional properties of channels and how
they impact neuronal excitability.
In a more recent study based on HCN candidate-gene screen-
ing of a small cohort of patients (n = 113), our group charac-
terized for the ﬁrst time a loss-of-function HCN2 mutation that
could be shown from functional studies to be directly involved in
human epilepsy (Figure 1). This study led to the identiﬁcation, in
a generalized epilepsy patient, of a homozygous recessive muta-
tion located in the C-linker region of HCN2 (E515K; Figure 1A)
that determines an almost complete loss of activity of the mutated
channel, leading to a signiﬁcant increase in the activity of neu-
ronal discharge, and of neuronal excitability (DiFrancesco et al.,
2011). As shown in Figure 1B, homozygous expression of E515K
mutated channels in acutely isolated newborn rat cortical neu-
rons led to a large negative shift of the Ih current activation
curve relative to wild-type channels, while heterozygous expres-
sion of wild type/E515K channels did not (Figure 1B), indicat-
ing that only recessive inheritance of the mutation will display
loss-of-function properties. In the neuronal model, following
administration of increasing doses of depolarizing current (range
10–50 pA), the transfection of both wild type and heterozygous
mutant channel reduced frequency discharge, compared to con-
trol conditions (empty-vector transfection) and transfection of
homozygous mutant channels (Figure 1C). These functional data
conﬁrm that HCN2 expression stabilizes excitability, and that
removal of HCN2 contribution in homozygous E515K variants
is associated with increased excitability, a condition predisposing
to epilepsy.
Later work from Nakamura and colleagues reported the ﬁnd-
ing in two unrelated patients with FS of a mutation in HCN2
(S126L) which endowed channels with a higher than normal
temperature sensitivity. Functional investigation showed that the
mutation leads to an increased Ih availability at high temperatures
(38◦C), whichmay contribute to hyperthermia-induced neuronal
hyperexcitability in FS (Nakamura et al., 2013).
More recently, using an exome sequencing approach, de
novo mutations in HCN1 have been identiﬁed for the ﬁrst time
in early infantile epileptic encephalopathy (EIEE; Nava et al.,
2014a). EIEE is a severe disease aﬀecting children within the
ﬁrst year of life which resembles the spectrum of Dravet syn-
drome and had been previously associated with mutations in
SCN1A sodium channel and PCDH19 (Depienne et al., 2009a,b).
According to the authors, the mutated HCN1 residues associated
with EIEE are all localized in the intracellular part of the chan-
nel, although one of them (S272) lies apparently well within the
S4 domain according to previously reported data (Santoro et al.,
1998). Interestingly, HCN1 exon deletions have been previously
reported in patients with autism spectrum disorders, but without
epilepsy (Nava et al., 2014b). The electrophysiological character-
ization of the mutations revealed for some of them a gain-of-
function eﬀect that could play a dominant-negative eﬀect, inter-
fering with the function of the remaining HCN1 alleles. Taken
together, these data suggest that point mutations altering HCN1
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FIGURE 1 | Human HCN2 E515K mutation and its effect on neuronal
excitability. 3D structure of hHCN2 C-linker and cyclic nucleotide binding
domain (CNBD) tetrameric domains based on X-ray crystallographic data
(Zagotta et al., 2003) and plotted as ribbon representation. Views shown are
perpendicular (left) and parallel (right) to fourfold axis; E515 residues are
drawn as space filling plots; the E515K mutation is located in the C-linker
region (A). When overexpressed in neonatal rat cortical neurons, the E515K
homozygous mutation leads to a large decrease of Ih in the voltage range of
current activation (left), due to a large negative shift of the activation curve
(right), when compared to both the wild-type (wt) and the heterozygous
mutation channel (wt/E515K) (B). Measurement of the firing rate due to
injection of various degrees of depolarizing currents (range 10–50 pA) shows
that neonatal rat cortical neurons transfected with either wild type or
heterozygous wild-type/mutant channels respond with a much-reduced
excitability than neurons transfected with empty vectors (controls) or with
homozygous E515K mutant channels (C). Mean threshold current required to
trigger action potential firing and mean rate of firing recorded upon current
injection in control, wt, wt/E515K, and E515K cells. Neuronal models
transfected with homozygous E515K mutant channels, like empty vectors,
show a significantly lower threshold current to trigger neuronal action
potential and a higher rate of firing action potential, upon depolarizing current
injection (D). Data from (DiFrancesco et al., 2011), with permission.
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channel function are poorly tolerated and predispose to neu-
ronal hyperexcitability, but are insuﬃcient by themselves to cause
seizure development. This is supported by data from experimen-
tal animal models of global HCN1 knockout, characterized by a
predisposition to the development of epilepsy, but without spon-
taneous seizures (Huang et al., 2009; Santoro et al., 2010). These
observations suggest that de novo HCN1mutations are associated
with EIEE, a particularly severe neurological phenotype, while
there is still no evidence for the involvement of HCN1 in IGE
(Tang et al., 2008; Dibbens et al., 2010; DiFrancesco et al., 2011).
Even if exhaustive genetic studies on a large cohort of patients
have not yet been performed, according to these preliminary
results (Table 1), HCN1 mutations seem to involve infantile,
severe, and progressive epileptic encephalopathies, while HCN2
appear to aﬀect patients with normal intellective level, with-
out evidence for a progressive disease. Interestingly, there is no
evidence yet for the involvement in epilepsy of dysfunctional
mutations in HCN4, despite this isoform is widely expressed in
the human brain. Figure 2 illustrates the rough sequence posi-
tions of mutations of HCN1 and HCN2 channels so far proposed
to be associated with epilepsy.
Hcn-Accessory Proteins
Dysfunctional behavior of the Ih current can also be medi-
ated by changes in the HCN-accessory proteins. This is a set
of proteins (such as MiRP1, Filamin A, TRIP8b, Caveolin 3,
tamalin, Mint2, S-SCAM, KCR1) that aﬀect the correct func-
tion of HCN ion channels by interaction at diﬀerent lev-
els (Yu et al., 2001; Gravante et al., 2004; Kimura et al., 2004;
Santoro et al., 2004, 2009; Barbuti et al., 2007b; Michels et al.,
2008; Biel et al., 2009; Noam et al., 2014). It is known for exam-
ple that the targeted deletion of MiRP1 leads to the down-
regulation of HCN channel function, which in turn is associ-
ated with increased excitability in neurons (Ying et al., 2012).
A more direct conﬁrmation of functional interaction between
channels and ancillary proteins comes from a study investi-
gating a single patient with long QT syndrome (LQT6) who
carried the M54T mutation in MiRP1 (Nawathe et al., 2013).
Since this patient was also symptomatic for bradycardia, a
condition not normally found in LQT patients, the study
explored possible changes in HCN function and found that
the M54T mutation indeed causes the HCN4 current den-
sity to decrease by about 80%, in agreement with the patient’s
bradycardia.
To our knowledge there is no established evidence so far
for a direct link between defective HCN accessory proteins and
neuronal hyperexcitability in epilepsy patients, although the pos-
sibility for such a dependence is likely to be signiﬁcant.
Anti Epileptic Drugs
An observation emphasizing the clinical relevance of the con-
cept of HCN-dependent epilepsy is that some anti-epileptic drugs
(AEDs) currently used for the treatment of patients have been
reported to modify the activity of the Ih current. For exam-
ple lamotrigine, widely used in clinical practice, reduces action
potential ﬁring and excitability in dendrites as a result of an
increased Ih, which provides an important potential mechanism
for its antiepileptic action (Poolos et al., 2002). In addition, the
antiepileptic drug gabapentin increases Ih in CA1 pyramidal neu-
rons (Surges et al., 2003) and acetazolamide, an inhibitor of car-
bonic anhydrase that has been used to treat epilepsy, can increase
Ih through intracellular alkalinization (Munsch and Pape, 1999).
These data conﬁrm the role played by the Ih current in the
epileptogenic process.
Pain
The sensation of pain is evoked when the body is exposed to
a potentially dangerous stimulus. This determines nerve mem-
brane depolarization and generation of action potentials from
peripheral nociceptors to CNS. Pain can generally be divided into
inﬂammatory and neuropathic.
Acute inﬂammatory pain has the crucial role of protecting
the body from external damage, thus lowering the risk of fur-
ther damage or infection of an injured area. It is triggered by
the release of inﬂammatory factors, such as prostaglandin E2
(PGE2) and enhances the ability of nociceptive nerve terminals
to generate action potentials, thus causing local hypersensitivity
(Linley et al., 2010). Typically, when the stimulus ceases, noci-
ceptive pain perception disappears. However, in certain circum-
stances, such as diabetes, or herpes zoster infection, inﬂammatory
pain becomes chronic, and seriously impairs the quality of life of
patients.
Neuropathic pain is a long-lasting pain state caused by nerve
injury, poorly treated by pharmacological drugs. Patients fre-
quently complain of painful spontaneous sensations, evoked by
normally harmless stimuli. While a major role of CNS sensory
TABLE 1 | Mutations of HCN1 and HCN2 in human epilepsy.
Gene Mutations Phenotype Biological effect Reference





Gain-of-function mutations with possible
dominant-negative effect (S100F, S272P,
R297T)
Nava et al. (2014a)
HCN2 R527Q Idiopathic generalized epilepsy No significant variation of Ih current Tang et al. (2008)
delPPP Febrile seizures (FS); genetic epilepsy
with FS plus (GEFS+)
Gain-of-function mutation Dibbens et al. (2010)
E515K Idiopathic generalized epilepsy Loss-of-function mutation DiFrancesco et al. (2011)
S126L FS Temperature-dependent shift of HCN2
channel kinetics
Nakamura et al. (2013)
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FIGURE 2 | Variants of HCN1 and HCN2 channels associated with epilepsy. Diagram representation of single human HCN1 (A) and HCN2 channel subunits
(B) showing the approximate position of mutations linked to infantile epileptic encephalopathy (HCN1) or inheritable forms of epilepsy (HCN2), as reported in the
literature. See text for further explanation.
processing is likely in neuropathic pain transmission, the condi-
tion of the injured peripheral nerve is critical for its initiation and
maintenance.
There is increasing evidence demonstrating a crucial role
played by the class of HCN ion channels in starting and con-
trolling ﬁring frequency of action potentials responsible for pain
(Jiang et al., 2008). Although the HCN1 isoform is one of the
pharmacological targets of the potent and widely used anesthetic
propofol (Tibbs et al., 2013), its contribution to the transmission
of pain seems to be limited. Recent experimental data have indeed
demonstrated the strategic role played by HCN2 in both inﬂam-
matory and neuropathic pain, suggesting the selective blocking of
its activity as a potential target for the treatment of pain.
Inflammatory Pain
It is established that the inhibition of the Ih current, by drugs
blocking HCN channels activity in a non-selective manner,
prevents inﬂammatory pain generated in various animal mod-
els by diﬀerent stimuli (Luo et al., 2007; Dunlop et al., 2009;
Takasu et al., 2010). However, these results do not allow to explain
the contribution of the speciﬁc channel isoforms involved in pain.
Selective genetic deletion of diﬀerent HCN isoforms recently
clariﬁed this important aspect.
According to studies in an HCN1 KO model, this channel iso-
form does not appear to play a crucial role in the transmission of
inﬂammatory pain (Momin et al., 2008). HCN2 global KO mod-
els have not been tested for the studies of pain, since they are
associated with severe neurological phenotypes, such as general-
ized epilepsy and ataxia, and are not prone to behavioral studies
(Ludwig et al., 2003; Chung et al., 2009).
Recently, a genetic approach using the selective deletion of
HCN2 in the NaV1.8 sensory neurons has contributed to clarify
the important role played by HCN2 in the generation and main-
tenance of pain. The study showed that the perception of pain
secondary to the administration of diﬀerent inﬂammatory stimuli
was lost inHCN2KOmice, while the reaction to acute pain in the
absence of inﬂammation remained unaltered. These data strongly
suggest that block of HCN2 can be considered as a putatively very
useful strategy for the treatment of inﬂammatory pain, without
the adverse eﬀect of reducing the perception of the normal acute
stimulus (Emery et al., 2011, 2012).
Neuropathic Pain
Non-selective pharmacological block of HCN channels also
inhibits neuropathic pain, suggesting their involvement in pain
perception caused by direct nerve injury. The genetic deletion
of HCN1 partially reduces the neuropathic pain determined
by direct damage on the nerve (Momin et al., 2008), while the
contribution of HCN2 appears to be more substantial. The ani-
mal model with a selective KO of HCN2 in NaV1.8-expressing
peripheral neurons shows the absence of hyperalgesia follow-
ing the application of diﬀerent nociceptive stimuli that deter-
mine nerve injury. These results support the notion that the
HCN2 isoform is a key factor in initiating neuronal excitabil-
ity following nerve damage and in the maintenance of neu-
ropathic pain. Accordingly, the selective inhibition of HCN2
activity could be expected to represent an interesting speciﬁc tar-
get for the treatment of this debilitating condition, widespread
in the general population. However, given the key role played
by HCN2 in the human CNS (DiFrancesco et al., 2011), any
speciﬁc HCN2-blocking drug used as a therapy against neu-
ropathic pain should be able to perfuse the peripheral ner-
vous system, without passing across the blood brain barrier, in
order to avoid serious neurological adverse consequence, such as
seizures.
It is also worth noticing that ivabradine, the unique clin-
ically approved non-selective HCN blocker used for coro-
nary heart disease and heart failure (DiFrancesco and Camm,
2004; DiFrancesco and Borer, 2007) has been reported to
reduce mechanical allodynia, inﬂammatory and neuropathic
pain in animal models, further supporting the involve-
ment of HCN channels in pain transmission (Noh et al.,
2014; Young et al., 2014). However, until more isoform-speciﬁc
drugs are commercially available, clinical use of ivabradine
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in the treatment of pain is obviously hindered by the
bradycardic eﬀect due to block of HCN4 activity in the
heart.
Parkinson’s Disease
Parkinson’s disease (PD) is one of the most common neu-
rodegenerative disease, characterized by progressive motor
symptoms such as bradykinesia, rigidity, and resting tremor
(Hammond et al., 2007; Ali and Morris, 2015). Progressive
degeneration of dopamine (DA) neurons in the substantia nigra
pars compacta (SNc) is the main etiology of PD.
HCN2 and HCN4 channels are highly expressed in midbrain
DA neurons, where they participate in the regulation of network
spontaneous activity (Mercuri et al., 1995; Santoro et al., 2000;
Notomi and Shigemoto, 2004; Chu and Zhen, 2010).
Recent data acquired from genetic and pharmacological ani-
mal models of PD reported a progressive downregulation of
HCN channel activity following DA depletion and DA neu-
ronal loss, although channel protein expression did not appear
to be aﬀected (Good et al., 2011). Interestingly, the delivery of
HCN subunits restored pacemaking activity and reduced burst
spiking, even if the motor disability induced by DA depletion
was not reversed (Chan et al., 2011). A role of HCN channel
downregulation in PD is also supported by a computational
model of the activity of the globus pallidus, which suggests a
possible mechanism for the emergence of parkinsonian activity
(Merrison-Hort and Borisyuk, 2013).
Recently, Masi et al. (2013) reported novel evidence for a pos-
sible inﬂuence of HCN channel dysfunction in the pathogenesis
of human PD. They showed that MPP+, a potent parkinsonizing
agent well known as a blocker of the mitochondrial complex I,
also leads to a dose-dependent inhibition of Ih in SNc DA neu-
rons. The electrophysiological analysis of this pharmacological
model revealed a reduced spontaneous activity of Ih in SNc DA
neurons, characterized by an increased responsiveness toward
synaptic excitation, possibly contributing to the pathogenesis of
human PD.
Conclusion
HCN channels play a fundamental role in the control of neu-
ronal excitability and network activity in the nervous sys-
tem. Accumulating evidence supports the view that modiﬁ-
cations in the HCN physiological function contribute to the
pathogenic mechanism leading to certain neurological dis-
eases in humans such as epilepsy, pain, and, as recently
emerged, PD.
Although it is now clear that HCN channels play an impor-
tant role in the pathogenesis of epilepsy, the precise mecha-
nisms underlying their role in this common disease still remains
to be elucidated. Thorough genetic studies of large popula-
tions of epileptic patients, able to associate the various forms
of epilepsy (i.e., absence, IGE, TLE, various type of epileptic
encephalopathies) to speciﬁc alterations of the channels, have yet
to be performed. However, preliminary results today available
suggest that HCN1 point mutations leading to channel dysfunc-
tion are associated with severe and progressive epileptic diseases,
while HCN2 mutations account for milder generalized pheno-
types, without evidence of a progressive feature. Interestingly,
there are no mutations of HCN channels reported in partial
epilepsies TLE, although the experimental data from animal
models allow to hypothesize their presence in humans. It will
certainly be necessary to better understand the role played by dys-
functional HCN channels in predisposing to the development of
the epileptogenic action potential. Understanding these aspects
will contribute to identify novel potential therapeutic strategies
for the treatment of epilepsy.
It is also important to note that the involvement of HCN
channels in a wide variety of neuronal processes including sen-
sory signal transduction, dendritic integration, synaptic plasticity,
pacemaking, and network oscillations, motor learning, and oth-
ers (Robinson and Siegelbaum, 2003) makes them likely contrib-
utors, when defective, to pathological behavior. As a natural con-
sequence of their contribution as neurological disease-causing
factors, HCN channels have long been considered an attrac-
tive therapeutic target (Postea and Biel, 2011; Reid et al., 2012;
Shah et al., 2013). It is interesting to note in this context that,
while most epilepsy-linked HCN mutations shown to gener-
ate hyperexcitability are loss-of-function (Lewis and Chetkovich,
2011), reduction of Ih activity is known to reduce chronic pain
(Emery et al., 2012; Young et al., 2014). The reason for this appar-
ently paradoxical eﬀect is that neuronal excitability depends
both on input membrane resistance and resting membrane volt-
age, whose Ih-linked modiﬁcations aﬀect excitability in oppo-
site ways (Poolos et al., 2002). It will be crucial in the near
future to clarify the details of HCN-associated excitatory vs.
inhibitory eﬀects, in order to identify speciﬁc pharmacologi-
cal strategies for these two clinical conditions, both extremely
common in the general population and poorly treated by con-
ventional drug therapy, and often characterized by multiple side
eﬀects.
The understanding of the processes rendering HCN chan-
nels dysfunctional in human neurological diseases will pro-
vide in the future further important insight into the molec-
ular mechanisms responsible for the disease, a concept likely
to be applicable to a larger number of ion channelopathies
than is known to date. While studies of animal models can
clearly provide essential basic information, it is highly desir-
able that further investigation is focused on the identiﬁcation
of the role played by HCN channelopathies in human dis-
eases. These studies should be eventually aimed at the devel-
opment of selective pharmacological strategies speciﬁcally tar-
geting HCN channels for the treatment of the neurological
diseases.
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